FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

Blood

Volumn 99, Issue 1, 2002, Pages 310-318

  Kelly, Louise M ^a,b   Liu, Qing ^a,b   Kutok, Jeffrey L ^a,b   Williams, Ifor R ^a,b   Boulton, Christina L ^a,b   Gilliland, D Gary ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; PROTEIN TYROSINE KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FLOW CYTOMETRY; GENE DUPLICATION; HISTOPATHOLOGY; MALIGNANT TRANSFORMATION; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; STEM CELL; TANDEM REPEAT; TARGET CELL;

EID: 0036093475     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.1.310     Document Type: Article

References (75)

1. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit
2. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1 1R family
3. Hematopoietic receptors of class III receptor-type tyrosine kinases
4. Cellular and molecular characterization of the role of the flk-2/flt-3 receptor tyrosine kinase in hematopoietic stem cells
5. Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase
6. FLT3: Receptor and ligand. Biology and potential clinical application
7. FLK-2/FLT-3 ligand regulates the growth of early myeloid progenitors isolated from human fetal liver
8. Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential
9. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines
10. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
11. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia
12. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia
13. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group
14. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
15. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product
16. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells
17. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
18. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation
19. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia
20. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children
21. The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts
22. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line
23. SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence
24. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adapter protein
25. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members
26. The TEL/platelet-derived growth factor β receptor (PDGFβR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFβR kinase-dependent signaling pathways
27. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
28. TEL/PDGFβR induces hematologic malignancy in mice that responds to the tyrosine kinase inhibitor CGP57148
29. Fatal myeloproliferation, induced in mice by TEL/PDGFβR expression, depends on PDGFβR tyrosines 579/581
30. TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: A common mechanism for transformation by tyrosine kinase fusion proteins
31. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia
32. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myeloid and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion gene
33. Stat5a/b is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2
34. Fusion of Huntingtin interacting protein 1 to PDGFβR in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2)
35. Transforming properties of the Huntingtin interacting protein 1/platelet-derived growth factor beta receptor fusion protein
36. Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR/ABL negative myeloprolifrative disorders with a t(5;10)(q33;q21)
37. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor β gene in atypical chronic myeloid leukemia with 1(5;10)(q33; q22)
38. Oligomerization of the ABL tyrosine kinase by the ETS protein TEL in human leukemia
39. Molecular abnormalities in myeloid leukemias and myelodysplastic syndromes
40. The novel activation of ABL by fusion to an ets-related gene, TEL
41. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9; 12) in a lymphoid and t(9;15;12) in a myeloid leukemia
42. Versatile retroviral vectors for potential use in gene therapy
43. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo
44. Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia
45. Silver impregnation of reticulum in paraffin sections
46. Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase
47. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEUJAK2
48. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: A novel model for chronic myelogenous leukemia
49. Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3
50. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences
51. Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice
52. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors
53. The fusion gene Cbfb-MYH 11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia
54. Analysis of the role of AML1-ETO in leukemo-genesis, using an inducible transgenic mouse model
55. Mitogenic signaling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells
56. Substrate specificities and identification of a putative binding site for Pl3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase
57. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways
58. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages
59. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines
60. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells
61. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling
62. c-Kit and c-kit mutations in mastocytosis and other hematological diseases
63. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
64. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3′-kinase activation and endothelial cell migration
65. The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: Synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors
66. Effects of human FLT3 ligand on myeloid leukemia cell growth: Heterogeneity in response and synergy with other hematopoietic growth factors
67. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors
68. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells
69. Hematologic effects of flt3 ligand in vivo in mice
70. Chronic expression of murine flt3 ligand in mice results in increased circulating white blood cell levels and abnormal cellular infiltrates associated with splenic fibrosis
71. Leukemic predisposition of mice transplanted with gene-modified hematopoietic precursors expressing flt3 ligand
72. Sensitivity to the abl inhibitor ST1571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease
73. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
74. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor